Dominari Holdings (STU:BP2A) ROCE % : -21.10% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dominari Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dominari Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -21.10%.

Dominari Holdings ROCE % Historical Data

The historical data trend for Dominari Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings ROCE % Chart

Dominari Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-50.88

-31.82

-14.62

-16.91

-32.88

Dominari Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-20.77	-52.11	-19.78	-39.38	-21.10

Dominari Holdings ROCE % Calculation

Dominari Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.987	/	( ( (71.967 - 1.689)	+	(52.781 - 1.474) )	/ 2 )
	=	-19.987	/	( (70.278	+	51.307)	/ 2 )
	=	-19.987	/	60.7925
	=	-32.88 %

Dominari Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-10.324	/	( ( (52.781 - 1.474)	+	(48.018 - 1.468) )	/ 2 )
	=	-10.324	/	( ( 51.307	+	46.55 )	/ 2 )
	=	-10.324	/	48.9285
	=	-21.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Dominari Holdings (STU:BP2A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dominari Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dominari Holdings (STU:BP2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (STU:BP2A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DOMH:USA

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Dominari Holdings (STU:BP2A) Headlines

No Headlines